Published in Brain Pathol on September 10, 2014
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med (2015) 5.03
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell (2016) 2.04
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther (2015) 1.19
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol (2015) 1.13
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol (2015) 1.11
Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol (2015) 1.01
The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics. Am J Pathol (2015) 0.99
IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget (2015) 0.99
Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011. J Neurooncol (2015) 0.98
Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol (2016) 0.96
Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol (2016) 0.94
Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol (2015) 0.94
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol (2016) 0.93
Protein residues that control the reaction trajectory in S-adenosylmethionine radical enzymes: mutagenesis of asparagine 153 and aspartate 155 in Escherichia coli biotin synthase. Biochemistry (2009) 0.93
Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol (2015) 0.93
Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol (2015) 0.91
Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol (2015) 0.89
Glioblastoma: molecular pathways, stem cells and therapeutic targets. Cancers (Basel) (2015) 0.89
Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. Neurology (2015) 0.87
Combination genetic signature stratifies lower-grade gliomas better than histological grade. Oncotarget (2015) 0.86
Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. Oncotarget (2016) 0.85
Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification. Semin Radiat Oncol (2015) 0.85
TERT Promoter Mutations and Risk of Recurrence in Meningioma. J Natl Cancer Inst (2015) 0.84
Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner. Neoplasia (2015) 0.84
EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA. Drugs Future (2016) 0.84
Liquid biopsies in patients with diffuse glioma. Acta Neuropathol (2015) 0.82
Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases. Am J Surg Pathol (2016) 0.82
The evolving molecular genetics of low-grade glioma. Adv Anat Pathol (2015) 0.82
Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Neuro Oncol (2016) 0.82
Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. J Neurosci (2015) 0.81
Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). J Neurooncol (2016) 0.81
Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol (2016) 0.81
ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. Oncoscience (2016) 0.79
Evolving Molecular Genetics of Glioblastoma. Chin Med J (Engl) (2016) 0.79
Letter in response to David N. Louis et al, International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading, Brain Pathology, doi: 10.1111/bpa.12171. Brain Pathol (2014) 0.79
CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. J Neuropathol Exp Neurol (2015) 0.79
PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status. Oncotarget (2016) 0.78
Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. Oncotarget (2016) 0.78
Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis. J Neurooncol (2016) 0.78
Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community. Neuro Oncol (2016) 0.78
68Ga-NOTA-Aca-BBN(7-14) PET/CT in Healthy Volunteers and Glioma Patients. J Nucl Med (2015) 0.78
Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6. Monoclon Antib Immunodiagn Immunother (2016) 0.78
PET imaging in glioma: is it time for mainstream practice? Neuro Oncol (2016) 0.78
Co-expression of mitosis-regulating genes contributes to malignant progression and prognosis in oligodendrogliomas. Oncotarget (2015) 0.78
Molecular characteristics of pediatric high-grade gliomas. CNS Oncol (2014) 0.78
Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups. Acta Neuropathol Commun (2016) 0.77
Pediatric gliomas as neurodevelopmental disorders. Glia (2015) 0.77
Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. Nat Commun (2016) 0.77
Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours. PLoS One (2015) 0.77
[Molecular diagnostics in neuropathology]. Pathologe (2015) 0.77
Targeting the Hedgehog Pathway in Pediatric Medulloblastoma. Cancers (Basel) (2015) 0.76
5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas. Sci Rep (2016) 0.76
A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel. Exp Mol Pathol (2015) 0.76
BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology. Acta Neuropathol (2016) 0.76
Cognitive Rehabilitation in Patients with Gliomas and Other Brain Tumors: State of the Art. Biomed Res Int (2016) 0.76
Automated Analysis of 1p/19q Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm. PLoS One (2015) 0.76
Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours. Eur Radiol (2015) 0.76
DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. Clin Epigenetics (2017) 0.75
Glioma: experimental models and reality. Acta Neuropathol (2017) 0.75
Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. Oncotarget (2016) 0.75
Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders. Cytokine Growth Factor Rev (2015) 0.75
IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation. Sci Rep (2016) 0.75
Deletion and low expression of NFKBIA are associated with poor prognosis in lower-grade glioma patients. Sci Rep (2016) 0.75
Next-generation sequencing of central nervous systems tumors: the future of personalized patient management. Neuro Oncol (2016) 0.75
TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. Int J Gynecol Pathol (2016) 0.75
Computational analysis of the mesenchymal signature landscape in gliomas. BMC Med Genomics (2017) 0.75
TSPO expression in brain tumours: is TSPO a target for brain tumour imaging? Clin Transl Imaging (2016) 0.75
Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults. J Mol Diagn (2016) 0.75
PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Acta Neuropathol Commun (2015) 0.75
Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neurooncol (2016) 0.75
Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis. Neurol Med Chir (Tokyo) (2016) 0.75
Prognostic Stratification of GBMs Using Combinatorial Assessment of IDH1 Mutation, MGMT Promoter Methylation, and TERT Mutation Status: Experience from a Tertiary Care Center in India. Transl Oncol (2016) 0.75
Imaging of oligodendroglioma. Br J Radiol (2016) 0.75
Alkaloids of fascaplysin are effective conventional chemotherapeutic drugs, inhibiting the proliferation of C6 glioma cells and causing their death in vitro. Oncol Lett (2016) 0.75
Cancer stem cells and microglia in the processes of glioblastoma multiforme invasive growth. Oncol Lett (2016) 0.75
Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas. Neuro Oncol (2016) 0.75
Copy Number Profiling of Brazilian Astrocytomas. G3 (Bethesda) (2016) 0.75
Extracranial oral cavity metastasis from glioblastoma multiforme: A case report. Mol Clin Oncol (2016) 0.75
Discrimination between two different grades of human glioma based on blood vessel infrared spectral imaging. Anal Bioanal Chem (2015) 0.75
Replication stress, DNA damage signalling, and cytomegalovirus infection in human medulloblastomas. Mol Oncol (2017) 0.75
Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas. Childs Nerv Syst (2016) 0.75
Molecular Testing of Brain Tumor. J Pathol Transl Med (2017) 0.75
Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. J Neurooncol (2017) 0.75
Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol (2017) 0.75
Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies. Clin Transl Oncol (2017) 0.75
Assessment of accessibility to the diagnosis and treatment of brain tumors in Argentina: Preliminary results. Surg Neurol Int (2017) 0.75
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Identification of human brain tumour initiating cells. Nature (2004) 38.87
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
International network of cancer genome projects. Nature (2010) 20.35
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Genetic pathways to primary and secondary glioblastoma. Am J Pathol (2007) 9.27
Genetic pathways to glioblastoma: a population-based study. Cancer Res (2004) 8.87
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol (2002) 8.60
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell (2006) 8.09
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol (2008) 7.79
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 7.73
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (2011) 6.67
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res (2008) 6.44
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol (2009) 6.43
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol (2012) 6.20
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol (2005) 6.16
Epidemiology and etiology of gliomas. Acta Neuropathol (2005) 6.14
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
Subtypes of medulloblastoma have distinct developmental origins. Nature (2010) 5.94
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One (2008) 5.86
Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med (2005) 5.81
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A (2013) 5.68
Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature (2008) 5.59
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature (2011) 5.49
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet (2009) 5.13
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med (2015) 5.03
Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery (2008) 5.03
Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol (2010) 4.94
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain (2010) 4.77
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol (2012) 4.70
Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol (2007) 4.68
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature (2011) 4.63
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet (2009) 4.52
Long-term survival with glioblastoma multiforme. Brain (2007) 4.51
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol (2009) 4.32
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A (2008) 4.14
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature (2012) 4.04
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol (2012) 4.00
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol (2009) 3.99
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet (2011) 3.93
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (2012) 3.88
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol (2010) 3.88
The definition of primary and secondary glioblastoma. Clin Cancer Res (2012) 3.84
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol (2006) 3.83
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res (2006) 3.83
PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell (2012) 3.83
Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature (2010) 3.70
Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med (2012) 3.67